Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report) EVP Scott Dreyer sold 2,255 shares of the stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $30.00, for a total value of $67,650.00. Following the transaction, the executive vice president now owns 124,421 shares of the company's stock, valued at approximately $3,732,630. This trade represents a 1.78 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
Collegium Pharmaceutical Stock Performance
COLL stock traded up $0.12 during mid-day trading on Friday, hitting $30.05. 2,287,750 shares of the company were exchanged, compared to its average volume of 417,801. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43. Collegium Pharmaceutical, Inc. has a 1-year low of $27.28 and a 1-year high of $42.29. The business has a 50 day simple moving average of $30.69 and a 200-day simple moving average of $32.71. The stock has a market capitalization of $946.15 million, a PE ratio of 12.95 and a beta of 0.99.
Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, beating analysts' consensus estimates of $1.54 by $0.09. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. The company had revenue of $181.95 million during the quarter, compared to the consensus estimate of $179.68 million. On average, equities analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current year.
Wall Street Analyst Weigh In
Several brokerages have recently weighed in on COLL. Piper Sandler decreased their price objective on Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating for the company in a report on Tuesday, February 4th. HC Wainwright restated a "buy" rating and issued a $50.00 price objective on shares of Collegium Pharmaceutical in a report on Friday, January 10th. Finally, Needham & Company LLC upgraded Collegium Pharmaceutical from a "hold" rating to a "buy" rating and set a $46.00 price objective for the company in a report on Friday, January 10th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, Collegium Pharmaceutical presently has an average rating of "Moderate Buy" and a consensus price target of $43.60.
View Our Latest Stock Analysis on Collegium Pharmaceutical
Institutional Investors Weigh In On Collegium Pharmaceutical
A number of hedge funds and other institutional investors have recently made changes to their positions in COLL. Invesco Ltd. increased its stake in Collegium Pharmaceutical by 19.5% in the fourth quarter. Invesco Ltd. now owns 1,775,760 shares of the specialty pharmaceutical company's stock valued at $50,876,000 after acquiring an additional 289,335 shares during the last quarter. Janus Henderson Group PLC increased its stake in Collegium Pharmaceutical by 319.4% in the fourth quarter. Janus Henderson Group PLC now owns 291,388 shares of the specialty pharmaceutical company's stock valued at $8,341,000 after acquiring an additional 221,903 shares during the last quarter. Victory Capital Management Inc. increased its stake in Collegium Pharmaceutical by 43.6% in the third quarter. Victory Capital Management Inc. now owns 710,688 shares of the specialty pharmaceutical company's stock valued at $27,461,000 after acquiring an additional 215,874 shares during the last quarter. JPMorgan Chase & Co. increased its stake in Collegium Pharmaceutical by 173.6% in the third quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company's stock valued at $10,711,000 after acquiring an additional 175,892 shares during the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Collegium Pharmaceutical in the fourth quarter valued at approximately $3,489,000.
Collegium Pharmaceutical Company Profile
(
Get Free Report)
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
Featured Stories
Before you consider Collegium Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Collegium Pharmaceutical wasn't on the list.
While Collegium Pharmaceutical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
